| Prev Close: | 233.07 |
|---|---|
| Open: | 229.37 |
| Bid: | 230.01 x 100 |
| Ask: | 234.99 x 100 |
| 1y Target Est: | 220.11 |
| Beta: | 1.29 |
| Next Earnings Date: | 22-Jul-13 |
| Day's Range: | 226.01 - 235.10 |
|---|---|
| 52wk Range: | 126.39 - 238.83 |
| Volume: | 1,231,116 |
| Avg Vol (3m): | 1,375,040 |
| Market Cap: | 55.22B |
| P/E (ttm): | 36.91 |
| EPS (ttm): | 6.30 |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Alkermes Earnings Beat Estimates, But Outlook Unclearat Investor's Business Daily(Thu 6:25PM EDT)
- Royalty Pharma eases condition for Elan offerAP(Thu 5:17PM EDT)
- Denner added as nominee to Vivus board by activist investorat Reuters(Thu 4:51PM EDT)
- Biogen Submits Plegridy BLAZacks(Thu 4:30PM EDT)
- Amgen Stock Checkup for Mayat Motley Fool(Thu 2:04PM EDT)
- Elan rejects Royalty's $6.4 billion raised offerReuters(Thu 1:36PM EDT)
- Elan rejects Royalty's $6.4 bln raised offerat Reuters(Thu 1:22PM EDT)
- Alkermes posts 4Q profit as royalty payments riseAP(Thu 12:44PM EDT)
- Jim Cramer: Buy Biogen Idec, Celgene, Clean Harbors, and This Stockat Wall St. Cheat Sheet(Thu 12:07PM EDT)
- Alex Denner Joins Vivus Activist Slate in Post-Icahn Moveat Bloomberg(Thu 9:35AM EDT)
- MS Patients Choose Death Risk With Potent Drug Treatmentat Bloomberg(Thu 8:22AM EDT)
- Biogen appoints Spyros Artavanis-Tsakonas as Chief Scientific Officertheflyonthewall.com(Thu 8:04AM EDT)
- InPlay: Biogen Idec appoints Spyros Artavanis-Tsakonas Chief Scientific OfficerBriefing.com(Thu 8:02AM EDT)
- Royalty cuts acceptance bar for Elan bid to 50 percentat Reuters(Thu 8:01AM EDT)
- Royalty cuts acceptance bar for Elan bid to 50 pctat Reuters(Thu 8:00AM EDT)
Press Releases
- Biogen Idec Appoints Spyros Artavanis-Tsakonas Chief Scientific OfficerBusiness Wire(Thu 8:00AM EDT)
- Biogen Idec to Present at the Deutsche Bank 38th Annual dbAccess Healthcare ConferenceBusiness Wire(Wed, May 22)
- Biogen Idec Submits Application to FDA for Approval of PLEGRIDY™ (Peginterferon Beta-1a) in Multiple SclerosisBusiness Wire(Tue, May 21)
Reports
- BIIB: Due Diligence Review: Forensic Earnings and ValuationNew Constructs, LLC(May 23)
- ValuEngine Detailed Valuation Report for BIIBValuEngine, Inc.(May 23)
- ValuEngine Industry Report for Medical-biomed/geneticsValuEngine, Inc.(May 23)